MARKET

IPSC

IPSC

Century Therapeutics, Inc.
NASDAQ
0.5881
-0.0372
-5.95%
Closed 16:25 03/18 EDT
OPEN
0.6306
PREV CLOSE
0.6253
HIGH
0.6486
LOW
0.5857
VOLUME
291.18K
TURNOVER
0
52 WEEK HIGH
5.24
52 WEEK LOW
0.5500
MARKET CAP
50.01M
P/E (TTM)
-0.3169
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at IPSC last week (0310-0314)?
Weekly Report · 2d ago
Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates
NASDAQ · 03/11 21:25
Weekly Report: what happened at IPSC last week (0303-0307)?
Weekly Report · 03/10 09:03
Weekly Report: what happened at IPSC last week (0224-0228)?
Weekly Report · 03/03 09:03
CENTURY THERAPEUTICS INC - RECEIVES NASDAQ NOTICE FOR BID PRICE DEFICIENCY
Reuters · 02/28 21:19
Weekly Report: what happened at IPSC last week (0217-0221)?
Weekly Report · 02/24 09:03
Century Therapeutics CEO Makes Significant Stock Sale
TipRanks · 02/21 02:08
Weekly Report: what happened at IPSC last week (0210-0214)?
Weekly Report · 02/17 09:03
More
About IPSC
Century Therapeutics, Inc. is a biotechnology company. The Company is focused on developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with unmet medical need. The Company has created allogeneic cell therapy platform that includes induced pluripotent stem cells (iPSCs), differentiation know-how to generate immune effector cells from iPSCs, or iPSC- derived cells, clustered regularly interspaced short palindromic repeats, to incorporate multiple transgenes and remove target genes. The Company’s product candidates include CNTY-101, CNTY-102, CNTY-107, CNTY-104, and CNTY-106. Its CNTY-101 is focused on targeting CD19 for relapsed, refractory B-cell lymphoma. CNTY-102 targets CD19 + CD22 for relapsed, refractory B-cell lymphoma and other B-cell malignancies. CNTY-107 is used of the treatment of solid tumors expressing Nectin-4. CNTY-106 is a multi-specific collaboration program for multiple myeloma.

Webull offers Century Therapeutics Inc stock information, including NASDAQ: IPSC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IPSC stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IPSC stock methods without spending real money on the virtual paper trading platform.